Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Ico Therapeutics, Inc. (OTC: ICOTF).

Full DD Report for ICOTF

You must become a subscriber to view this report.


Recent News from (OTC: ICOTF)

iCo Therapeutics Announces Additional Positive Pharmacokinetic Results and Presentation at Global Investment Conference
Vancouver, British Columbia--(Newsfile Corp. - September 6, 2018) - iCo Therapeutics ("iCo" or the "Company") (TSXV: ICO) (OTCQB: ICOTF), today announced additional positive pharmacokinetic data from its recent Phase 1 study of its Oral Amphotericin B (Oral Amp B) candidate. Previously the Com...
Source: Newsfile
Date: September, 06 2018 08:00
iCo Therapeutics Announces Second Quarter 2018 Financial Results And Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - August 29, 2018) - iCo Therapeutics  (TSXV: ICO) (OTCQB: ICOTF)  ("iCo" or the "Company"), today reported financial results for the quarter and six months ended June 30, 2018. Amounts, unless specified otherwise, are expressed in Cana...
Source: Newsfile
Date: August, 29 2018 18:32
InvestorsGuru.com 10 Filtered Mid-Day Market Movers Recap
Mid-Day Market Movers focus on above average volume, price action, breakout chart trends and news - posted throughout the day live at the top of InvestorsGuru.com and on our Hot Sheet , or follow our @InvestorsGuru Twitter feed or Facebook.com/InvestorsGuru page. Below recaps last week...
Source: Investors Guru
Date: August, 12 2018 12:07
iCo Therapeutics Announces Positive Secondary Endpoint and Advancement into Later Stage Clinical Trials - Phase 1 Oral Amphotericin B
Vancouver, British Columbia--(Newsfile Corp. - July 16, 2018) - iCo Therapeutics Inc.  (TSXV: ICO) (OTCQB: ICOTF)  ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., today announced a positive pharmacokinetic secondary end point in its Phase 1 clinical...
Source: Newsfile
Date: July, 16 2018 08:01
InvestorsGuru.com 12 Filtered Mid-Day Market Movers Recap
Mid-Day Market Movers focus on above average volume, price action, breakout chart trends and news - posted throughout the day live at the top of InvestorsGuru.com and on our Hot Sheet , or follow our @InvestorsGuru Twitter feed or Facebook.com/InvestorsGuru page. Below recaps last week...
Source: Investors Guru
Date: July, 15 2018 08:44
iCo Therapeutics Announces Positive Clinical Outcome - Primary Endpoint Met in Phase 1 Oral Amphotericin B Study
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., today announced a positive primary end point in its Phase 1 clinical study. The study met its prima...
Source: Newsfile
Date: June, 27 2018 08:00
iCo Therapeutics Provides Corporate Update, Announces Completion of Phase 1 Recruitment
Vancouver, British Columbia--(Newsfile Corp. - June 20, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today announced the completion of recruitment of all 32 subjects in the Company's Phase 1 Oral Amphotericin B (Oral Amp B) study. Phase 1 Oral Amp B Clin...
Source: Newsfile
Date: June, 20 2018 08:00
iCo Therapeutics Announces First Quarter 2018 Financial Results And Update On Phase 1 Clinical Trial
Vancouver, British Columbia--(Newsfile Corp. - May 30, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported financial results for the quarter ended March 31, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under...
Source: Newsfile
Date: May, 30 2018 16:18
iCo Therapeutics Announces Year End 2017 Financial Results
Vancouver, British Columbia--(Newsfile Corp. - April 24, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported financial results for the year ended December 31, 2017. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented und...
Source: Newsfile
Date: April, 24 2018 20:47
iCo Therapeutics Announces Major Milestone - Dosing of First Patient for its Oral Amphotericin B Phase 1 Clinical Study
Vancouver, British Columbia--(Newsfile Corp. - April 18, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., today announced that it has dosed the first patient in its Phase 1 clinical study for Oral Amphote...
Source: Newsfile
Date: April, 18 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-17N/A0.0398N/AN/A0
2018-12-14N/A0.0398N/AN/A0
2018-12-130.03980.03980.03980.0398500
2018-12-12N/A0.0433N/AN/A0
2018-12-11N/A0.0433N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-11-21502,0502.4390Cover
2018-11-065,0005,000100.0000Short
2018-10-2270,000120,00058.3333Short
2018-10-0238,00045,95882.6842Short
2018-09-281,1875,68720.8722Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ICOTF.


About Ico Therapeutics, Inc. (OTC: ICOTF)

Logo for Ico Therapeutics, Inc. (OTC: ICOTF)

iCo Therapeutics in licenses and redefines existing drug candidates or generics by employing reformulation and delivery technologies for new or expanded use indications. The Company holds worldwide rights to an oral drug delivery platform, with Oral Amphotericin B Amp B as the initial platform candidate, utilizing a known anti fungal drug to treat life threatening infectious diseases. iCo also has worldwide rights to iCo , a monoclonal antibody targeting eotaxin . With Phase clinical history, Bertilimumab iCo is candidate for the treatment of vernal or atopic keratoconjunctivitis. iCo is in Phase clinical studies with iCo s partner, Immune Pharmaceuticals.

 

 

 

Current Management

  • Andrew Rae / President, CEO
  • Michael Liggett / CFO
  • Peter Hnik / Chief Med. Officer
  • William Jarosz /
  • Susan Koppy /
  • Andrew Rae /

Current Share Structure

  • Market Cap: $2,119,889 - 03/13/2018
  • Issue and Outstanding: 84,457,713 - 01/17/2018
  • Float: 79,904,458 - 01/17/2018

 


Recent Filings from (OTC: ICOTF)

Quarterly Report - CFO Certification
Filing Type: Quarterly Report - CFO CertificationFiling Source: OTC Markets
Filing Date: November, 29 2017
Quarterly Report - CEO Certification
Filing Type: Quarterly Report - CEO CertificationFiling Source: OTC Markets
Filing Date: November, 29 2017
Quarterly Report - MD&A Q3 2017
Filing Type: Quarterly Report - MD&A Q3 2017Filing Source: OTC Markets
Filing Date: November, 29 2017
Quarterly Report - iCo Q3 2017 Financial Statements
Filing Type: Quarterly Report - iCo Q3 2017 Financial StatementsFiling Source: OTC Markets
Filing Date: November, 29 2017

 

 


Daily Technical Chart for (OTC: ICOTF)

Daily Technical Chart for (OTC: ICOTF)


Stay tuned for daily updates and more on (OTC: ICOTF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ICOTF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ICOTF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ICOTF and does not buy, sell, or trade any shares of ICOTF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/